Ampio Pharmaceuticals begins phase 1 trial of Ampion for COVID-19 treatment
Ampio Pharmaceuticals has started a phase 1 clinical trial in the US for assessing its immunomodulatory anti-inflammatory agent Ampion as a five-day intravenous (IV) treatment for COVID-19 in adult patients who need supplemental oxygen. According to the Colorado-based biopharma company, the primary endpoint for the randomized, controlled study – NCT04456452 is the safety and tolerability […]
Noxopharm, an Australian clinical-stage pharma company, has started the phase 1 NOXCOVID-1 clinical trial for Veyonda in Europe to evaluate the anti-cancer drug candidate as a potential treatment for cytokine storm and septic shock in COVID-19 patients. With a capability to inhibit cGAS-STING signalling, Veyonda can potentially block the start of the cytokine storm which […]
Continue reading …CytoAgents, Quotient Sciences to take COVID-19 drug candidate GP1681 into human trials
April 29, 2020 1 Comment
US biotech company CytoAgents has joined forces with CDMO and CRO services provider Quotient Sciences to accelerate the development of its COVID-19 drug candidate GP1681 into human clinical trials for the treatment of cytokine storm. According to the partners, scientific consensus is building that severe illness resulting from COVID-19 and other infectious diseases is triggered by […]
Continue reading …
Business News Today
- MedCrypt acquires medical device cybersecurity software firm MedISAO
- Improving acquires custom software development firm Object Partners
- High Street Insurance acquires Michigan-based Capital Insurance Group
- Mill Creek Residential breaks ground on Modera Washington in Houston
- Cincinnati-based RIA Lenox Wealth Management acquired by Creative Planning
- Jersey Elevator acquired by Arcline Investment Management
- U.S. Gold acquires Northern Panther Resource, owner of Challis gold project
- Perrigo acquires skincare and hair loss treatment brands from Sanofi
- Bayer to acquire KaNDy Therapeutics to add menopause drug candidate
- Thoma Bravo to acquire US insurtech Majesco for higher price of $729m
